CellaVision AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
October 25, 2023 at 01:20 am EDT
Share
CellaVision AB (publ) reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported sales was SEK 167.9 million compared to SEK 141.03 million a year ago. Net income was SEK 25.96 million compared to SEK 10.38 million a year ago. Basic earnings per share from continuing operations was SEK 1.09 compared to SEK 0.44 a year ago.
For the nine months, sales was SEK 476.66 million compared to SEK 487.02 million a year ago. Net income was SEK 79.88 million compared to SEK 86.04 million a year ago. Basic earnings per share from continuing operations was SEK 3.35 compared to SEK 3.61 a year ago.
CellaVision AB is a Sweden-based company active in the medical technology sector. The Company develops and sells digital solutions for medical microscopy, as well as products enabling blood cell analysis and morphology diagnosis. CellaVision ABâs product portfolio consists of analyzers for automated medical microscopy analysis and software applications designed for remote access, competency testing and education. The analyzers include such brands as CellaVision DM96 and CellaVision DM1200, whereas the software applications are divided into CellaVision Body Fluid Application, CellaVision Remote Review Software and CellaVision Competency Software, among others. The Company operates four subsidiaries, based in Sweden, Canada, the United States and Japan. In June 2014, CellaVision AB acquired technology platform from Clear Lake Medical Foundation.
CELLAVISION AB 
